Larvol Delta - Centessa-Pharmaceuticals-Announces-FDA-Clearance-of-IND-Application-for-Phase-12a-Clinical-Trial-of-LB101-First-LockBody-Candidate-for-Solid-Tumors

LB101 - Centessa

https://www.globenewswire.com/news-release/2023/01/26/2596144/0/en/Centessa-Pharmaceuticals-Announces-FDA-Clearance-of-IND-Application-for-Phase-1-2a-Clinical-Trial-of-LB101-First-LockBody-Candidate-for-Solid-Tumors.html

Jan 26, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next